AptarGroup (NYSE:ATR) Releases Earnings Results, Beats Estimates By $0.05 EPS

AptarGroup (NYSE:ATR) announced its quarterly earnings data on Thursday. The industrial products company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.47 by $0.05, Zacks reports. AptarGroup had a net margin of 6.69% and a return on equity of 13.08%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $980.76 million. During the same quarter in the previous year, the firm posted $1.62 earnings per share. The company’s revenue for the quarter was up 6.0% on a year-over-year basis.

AptarGroup Stock Performance

Shares of AptarGroup stock traded up $6.18 during trading hours on Friday, reaching $136.82. The company’s stock had a trading volume of 1,007,389 shares, compared to its average volume of 484,098. AptarGroup has a one year low of $103.23 and a one year high of $146.91. The stock has a market cap of $8.70 billion, a P/E ratio of 33.21, a price-to-earnings-growth ratio of 4.05 and a beta of 0.34. The company’s 50 day simple moving average is $125.87 and its 200 day simple moving average is $127.01. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.10 and a current ratio of 1.61.

AptarGroup Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Thursday, November 12th will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.5%. The ex-dividend date of this dividend is Thursday, November 12th. This is a positive change from AptarGroup’s previous quarterly dividend of $0.48. AptarGroup’s dividend payout ratio is currently 46.60%.

Key Headlines Impacting AptarGroup

Here are the key news stories impacting AptarGroup this week:

• Positive Sentiment: Q3 results topped estimates: AptarGroup reported adjusted earnings of $1.52 per share, above the $1.47 consensus estimate, while revenue rose 6.0% year over year to approximately $1.02 billion, ahead of expectations near $981 million. AptarGroup Q3 Earnings and Revenues Beat Estimates
• Positive Sentiment: Dividend raised: The quarterly dividend was increased 4.2% to $0.50 per share, or $2.00 annually. The dividend is payable December 3 to shareholders of record as of November 12, supporting the company’s shareholder-return profile. Aptar Increases Quarterly Dividend
• Neutral Sentiment: Growth came with mixed profitability: Revenue and gross profit increased, but adjusted earnings declined from $1.62 per share a year earlier. Reported operating profit also slipped modestly, suggesting that margins remain an area investors will monitor. AptarGroup Q3 Earnings Update
• Neutral Sentiment: Management commentary is now in focus: The Q3 earnings-call transcript may provide additional insight into demand trends, margins, capital spending, and the company’s outlook for the remainder of 2026. AptarGroup Q3 2026 Earnings Call Transcript
• Negative Sentiment: Insider selling is a risk signal: Recent disclosures cited multiple insider sales and no insider purchases over the past six months. This does not necessarily indicate deteriorating fundamentals, but it could temper investor enthusiasm. AptarGroup Q3 2026 Earnings and Trading Data

Insider Buying and Selling at AptarGroup

In other news, insider Shiela Vinczeller sold 765 shares of AptarGroup stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $130.37, for a total value of $99,733.05. Following the transaction, the insider directly owned 26,313 shares of the company’s stock, valued at $3,430,425.81. This trade represents a 2.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Stephan Tanda sold 9,838 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $136.16, for a total value of $1,339,542.08. Following the sale, the chief executive officer owned 238,729 shares of the company’s stock, valued at approximately $32,505,340.64. This trade represents a 3.96% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 23,197 shares of company stock valued at $3,134,828 in the last ninety days. Company insiders own 0.73% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ATR. Raymond James Financial reissued an “outperform” rating and set a $160.00 price target on shares of AptarGroup in a research report on Wednesday, July 15th. UBS Group started coverage on shares of AptarGroup in a research note on Friday, October 9th. They issued a “neutral” rating and a $135.00 price objective for the company. Wells Fargo & Company raised their target price on shares of AptarGroup from $145.00 to $155.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Weiss Ratings restated a “hold (c)” rating on shares of AptarGroup in a research note on Monday, September 21st. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on AptarGroup in a research note on Wednesday, October 7th. They issued a “buy” rating and a $150.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, AptarGroup currently has an average rating of “Moderate Buy” and a consensus target price of $164.14.

AptarGroup Company Profile

AptarGroup, Inc (NYSE: ATR) develops and manufactures dispensing, sealing and delivery systems for the pharmaceutical, beauty, personal care, food and beverage markets. Its products are designed to control, protect and dispense a wide range of liquids, creams, lotions, fragrances and other formulations.

The company’s offerings include pumps, valves, closures, aerosol systems and other dispensing components, as well as drug-delivery technologies. Through its pharmaceutical business, Aptar supports nasal, pulmonary, ophthalmic, dermal and injectable applications, serving pharmaceutical and biotechnology companies with components and systems used in prescription, over-the-counter and consumer health products.

Aptar serves customers internationally through manufacturing, research and development and commercial operations across North America, Europe, Asia and other global markets.